C4 Therapeutics Q3 EPS Miss, Revenue Exceeds Expectations Amid Pipeline Momentum

miércoles, 26 de noviembre de 2025, 6:29 am ET1 min de lectura
CCCC--

C4 Therapeutics reported a GAAP EPS loss of -$0.44 for 3Q25, missing analyst estimates by $0.03. However, revenue of $11.23 million beat expectations by $4.95 million. The company's pipeline momentum remains strong despite the miss.

C4 Therapeutics Q3 EPS Miss, Revenue Exceeds Expectations Amid Pipeline Momentum

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios